Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14076496 | 0.85 | LMNA (0.48) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL12536051 | 0.82 | KMT2A (0.52) | LMNAALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL10272444 | 0.81 | LMNA (0.64) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL13844981 | 0.81 | POLB (0.41) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL4545466 | 0.80 | EPHX2 (0.53) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL10272620 | 0.79 | POLB (0.69) | SMN1; SMN2LMNAALDH1A1RAB9AHPGD | |
| SCHEMBL19225206 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL963712 | 0.79 | EPHX2 (0.70) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL13218160 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL13142435 | 0.78 | SLC6A3 (0.43) | LMNAALDH1A1GAATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196201-B1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-3757105-A2 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | Shionogi & Co., Ltd (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3196201-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100204237-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | MIKAMIYAMA HIDENORI | 2010-08-12 | — | — | US | disclosed |
| US-7745453-B2 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| CN-101513402-A | Antiviral agent | SHIONOGI & CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| CN-100491349-C | Antiviral agent | SHIONOGI & CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | HAT1, SULT1A1, CDK20 | SMN1; SMN2 1918/4885LMNA 3192/4885ALDH1A1 340/4885 |
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | SMN1; SMN2 3953/4885LMNA 2825/4885ALDH1A1 658/4885 |
| US-20100204237-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | HAT1, SULT1A1, CDK20 | SMN1; SMN2 1918/4885LMNA 3192/4885ALDH1A1 340/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | SMN1; SMN2 4086/4885LMNA 1344/4885ALDH1A1 1332/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | SMN1; SMN2 3746/4885LMNA 2945/4885ALDH1A1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.